Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

I have to correct my post regarding a very very preliminary abstract.

Last year this very very preliminary abstract gave an inkling of what was to come since the trial only started on St Patty’s Day (March 17th) but if history repeats itself this year and an abstract is released electronically in JTO there should be a lot more detail. Heck, WCLC starts 3 weeks earlier this year so if everything is repeated this year as it was last year, this very very preliminary abstract, if it came out 3 weeks earlier would come out at the end of May to the beginning of June! (note – this very very preliminary abstract coming out is all speculation on my part; I’m not privy to JTO I’m just observing what happened last year)

I thought it may have come out at the end of June last year since somewhere I saw (imagined? Yes, what I saw I think was a date to a workshop) that the Journal reference was dated June. Since this abstract is correlated to WCLC in Sept which is 3 weeks earlier than last year starting on Sept 23rd, I would have thunk that the very very preliminary abstract would be available (think of it as a placeholder abstract) but nothing available yet. The reason I bring this up now is that I was just reading an Investopedia article that came out today titled “Top 4 Small-Cap Stocks for 2018” that discusses SPPI.

This small-cap stock had a high-volume breakout in November 2016, and after moving sideways for a while, it moved sharply higher. The stock price soared again at the end of September 2017 on news that lung cancer drug poziotinib showed success in early clinical trials. More positive news on the drug sent the stock even higher in October. After these 2017 gains and a rather volatile performance in the first half of this year, this biotech play could still be a winner in the remainder of 2018 for investors who believe that the stock has more room to run. A recent Bloomberg report indicates that the company is considering a sale, which has the stock trading at $22.49, just slightly under its 2018 high. (See also: Spectrum Q2 Loss Narrower Than Expected, Sales Beat.)
Read more: Top 4 Small-Cap Stocks for 2018 | Investopedia https://www.investopedia.com/investing/top-small-cap-stocks/#ixzz5KqrMuVpr
Follow us: Investopedia on Facebook

Investipedia stated i.e. “The stock price soared again at the end of September 2017 on news that lung cancer drug poziotinib showed success in early clinical trials” which coincided w the PR/abstract release around Sept 5th and “More positive news on the drug sent the stock even higher in October” coincided with the CC during the conference. Anyhows, the fireworks will start 3 weeks earlier than last year, around Sept 5th (release of abstracts), as opposed to the end of Sept. There was a rise from $7.33 on Aug 3rd to $8.96 on Aug 4th last year. I suspect this is when the preliminary abstract came out but can’t be sure of it since I didn’t find out about the preliminary abstract till towards the end of Sept last year (but I'll be paying attention this year). So, I stand corrected. This very very preliminary abstract I would expect to see towards the end of July, perhaps August with the full abstract available Sept 5th (w SPPI PR noting it), and CC update during WCLC around Sept 24th.